valproic acid has been researched along with Mood Disorders in 85 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 8.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| " 58 years old female with pancytopenia in the course of acute valproic acid intoxication was described." | 7.77 | [Pancytopenia in the course of acute valproic acid poisoning--case report]. ( Klimaszyk, D; Łukasik-Głebocka, M, 2011) |
| "The authors report the case of a patient who developed hyperammonemia and coma during therapy with valproic acid for affective disorder." | 7.70 | Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. ( Donley, B; Eze, E; Workman, M, 1998) |
| "Affective disorders have a substantial public health impact due to morbidity, mortality, quality of life impairment and economic implications." | 6.41 | [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness]. ( Ahrens, B; Becker, T; Roick, C, 2001) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 4.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "In an attempt to find the key to reducing the excessive morbidity and mortality seen with mood disorders, our laboratory has been extensively investigating lithium's mechanisms of action in an integrated series of clinical and preclinical studies." | 4.80 | Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. ( Bebchuk, JM; Chen, G; Glitz, D; Hasanat, KA; Manji, HK; Moore, GJ, 1999) |
| "Controlled studies of lithium, valproate and carbamazepine in preventing future episodes of affective disorders were classified according to methodological rigour, and meta-analyses were performed overall and on each type." | 4.80 | Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. ( Davis, JM; Hogan, DM; Janicak, PG, 1999) |
| " We describe the phenomenon of amygdala-kindled seizures episodically breaking through effective daily pharmacotherapy with carbamazepine and valproate, suggesting that these observations could reflect the balance of pathological vs compensatory illness-induced changes in gene expression." | 4.79 | A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. ( Post, RM; Weiss, SR, 1996) |
| "Patients with major affective disorders are more likely to complete suicide than patients in any other medical group." | 3.79 | Anticonvulsant therapy and suicide risk in affective disorders. ( Goodwin, FK, 1999) |
| " 58 years old female with pancytopenia in the course of acute valproic acid intoxication was described." | 3.77 | [Pancytopenia in the course of acute valproic acid poisoning--case report]. ( Klimaszyk, D; Łukasik-Głebocka, M, 2011) |
| "The use of lithium carbonate for the treatment of mood disorders in old age has decreased at a dramatic rate in favor of valproate." | 3.73 | Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. ( Anderson, G; Bronskill, S; Gill, S; Mamdani, M; Rochon, P; Shulman, KI; Sykora, K; Wodchis, WP, 2005) |
| "The authors report the case of a patient who developed hyperammonemia and coma during therapy with valproic acid for affective disorder." | 3.70 | Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder. ( Donley, B; Eze, E; Workman, M, 1998) |
| "Substance abuse is a common comorbid illness in patients with mood disorders." | 2.69 | Divalproex sodium in substance abusers with mood disorder. ( Albanese, MJ; Clodfelter, RC; Khantzian, EJ, 2000) |
| "Substantial pharmacokinetic changes can occur during pregnancy in a number of commonly used antidepressants and mood stabilizers." | 2.50 | Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. ( Byatt, N; Deligiannidis, KM; Freeman, MP, 2014) |
| "The mood disorders-primarily major depressive disorder and bipolar affective disorder-constitute one of the world's greatest public health problems and are associated with significant reductions in productivity, health, and longevity." | 2.44 | Pharmacotherapy of mood disorders. ( Denko, T; Thase, ME, 2008) |
| "Agents introduced for the treatment of epilepsy have also been usedsimultaneously for psychiatric indications." | 2.43 | [Anticonvulsants treatment of psychiatric disorder in elderly patients]. ( Bidzan, L, 2006) |
| "Mood disorders have traditionally been conceptualized as neurochemical disorders, but there is now evidence from a variety of sources demonstrating regional reductions in central nervous system (CNS) volume, as well as reductions in the numbers and/or sizes of glia and neurons in discrete brain areas." | 2.42 | The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. ( Du, J; Gray, NA; Manji, HK; Moore, GJ; Zhou, R, 2003) |
| "Valproic acid (VPA) is an antiepileptic drug with mood-stabilizing properties." | 2.42 | Search for a common mechanism of mood stabilizers. ( Agam, G; Harwood, AJ, 2003) |
| "Affective disorders have a substantial public health impact due to morbidity, mortality, quality of life impairment and economic implications." | 2.41 | [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness]. ( Ahrens, B; Becker, T; Roick, C, 2001) |
| " The newer anticonvulsants felbamate, lamotrigine, topiramate, and tiagabine have different hepatically-mediated drug-drug interactions, while the renally excreted gabapentin lacks hepatic drug-drug interactions but may have reduced bioavailability at higher doses." | 2.40 | Metabolism and excretion of mood stabilizers and new anticonvulsants. ( Corá-Locatelli, G; Frye, MA; Ketter, TA; Kimbrell, TA; Post, RM, 1999) |
| " This was achieved safely through a reduced dosing schedule of three times a week post dialysis, slow dose titration and blood level monitoring prior to each dialysis session." | 1.62 | Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy. ( Salisbury, E; Topp, S, 2021) |
| "Topiramate was more likely prescribed for those with comorbid headache or migraine (incident: 335 of 1251 [26." | 1.51 | Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy. ( Faught, E; Fishman, J; Kalilani, L; Kim, H; Thurman, DJ, 2019) |
| "Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder." | 1.43 | Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Rowe, M; Suppes, T, 2016) |
| "Co-morbid substance abuse was uncommon." | 1.39 | Prevalence and clinical presentation of HIV positive female psychiatric inpatients. ( Uys, H, 2013) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.35) | 18.7374 |
| 1990's | 17 (20.00) | 18.2507 |
| 2000's | 42 (49.41) | 29.6817 |
| 2010's | 20 (23.53) | 24.3611 |
| 2020's | 4 (4.71) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, AM | 1 |
| Weinshilboum, RM | 1 |
| Frye, MA | 3 |
| Biernacka, JM | 1 |
| Pigoni, A | 1 |
| Mandolini, GM | 1 |
| Delvecchio, G | 1 |
| Bressi, C | 1 |
| Soares, JC | 1 |
| Brambilla, P | 1 |
| Sharma, A | 1 |
| Sinha, S | 1 |
| Narang, A | 1 |
| Chouhan, DK | 1 |
| Gupta, S | 1 |
| Topp, S | 1 |
| Salisbury, E | 1 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 1 |
| Marino, P | 1 |
| Schulberg, HC | 1 |
| Gildengers, AG | 1 |
| Mulsant, BH | 1 |
| Sajatovic, M | 1 |
| Gyulai, L | 1 |
| Aljurdi, RK | 1 |
| Evans, LD | 1 |
| Banerjee, S | 1 |
| Gur, RC | 1 |
| Young, RC | 1 |
| Carmassi, C | 1 |
| Del Grande, C | 1 |
| Masci, I | 1 |
| Caruso, D | 1 |
| Musetti, L | 1 |
| Fagiolini, A | 1 |
| Dell'Osso, L | 1 |
| Kim, H | 1 |
| Faught, E | 1 |
| Thurman, DJ | 1 |
| Fishman, J | 1 |
| Kalilani, L | 1 |
| Uys, H | 1 |
| Abe, Y | 1 |
| Yasugawa, S | 1 |
| Miyamoto, K | 1 |
| Terao, T | 1 |
| Santos-Cubiñá, J | 1 |
| Torres-Rodríguez, A | 1 |
| Castaing-Lespier, PA | 1 |
| Sabaté, N | 1 |
| Torres-Martin, A | 1 |
| Carlo, S | 1 |
| Deligiannidis, KM | 1 |
| Byatt, N | 1 |
| Freeman, MP | 1 |
| Mauer, S | 1 |
| Alahmari, R | 1 |
| Vöhringer, PA | 1 |
| Vergne, DE | 1 |
| Lövdahl, H | 1 |
| Correa, E | 1 |
| Patkar, A | 1 |
| Pae, C | 1 |
| Strejilevich, S | 1 |
| Dalley, S | 1 |
| Ghaemi, SN | 1 |
| Kowalski, PC | 1 |
| Dowben, JS | 1 |
| Keltner, NL | 1 |
| Post, RM | 4 |
| Leverich, GS | 1 |
| Kupka, R | 1 |
| Keck, PE | 1 |
| McElroy, SL | 1 |
| Altshuler, LL | 1 |
| Rowe, M | 1 |
| Grunze, H | 1 |
| Suppes, T | 1 |
| Nolen, WA | 1 |
| Landgraf, D | 1 |
| Joiner, WJ | 1 |
| McCarthy, MJ | 1 |
| Kiessling, S | 1 |
| Barandas, R | 1 |
| Young, JW | 1 |
| Cermakian, N | 1 |
| Welsh, DK | 1 |
| Pisanu, C | 1 |
| Papadima, EM | 1 |
| Del Zompo, M | 1 |
| Squassina, A | 1 |
| Sümegi, A | 1 |
| Chang, K | 1 |
| Karchemskiy, A | 1 |
| Kelley, R | 1 |
| Howe, M | 1 |
| Garrett, A | 1 |
| Adleman, N | 2 |
| Reiss, A | 1 |
| Machado-Vieira, R | 1 |
| Ibrahim, L | 1 |
| Zarate, CA | 2 |
| Tarr, GP | 1 |
| Glue, P | 1 |
| Herbison, P | 1 |
| Weiss, SR | 2 |
| Nanavati, D | 1 |
| Austin, DR | 1 |
| Catapano, LA | 1 |
| Luckenbaugh, DA | 1 |
| Dosemeci, A | 1 |
| Manji, HK | 5 |
| Chen, G | 3 |
| Markey, SP | 1 |
| Gazdag, G | 1 |
| Takács, R | 1 |
| Ungvari, GS | 1 |
| Klimaszyk, D | 1 |
| Łukasik-Głebocka, M | 1 |
| Bocchetta, A | 1 |
| Siddu, A | 1 |
| Sardu, C | 1 |
| Sarnicola, A | 1 |
| Martinelli, V | 1 |
| Maksutova, EL | 1 |
| Zheleznova, EV | 1 |
| Sokolova, LV | 1 |
| Scott, J | 2 |
| Pope, M | 1 |
| Tariot, PN | 1 |
| Loy, R | 1 |
| Ryan, JM | 1 |
| Porsteinsson, A | 1 |
| Ismail, S | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Macritchie, K | 1 |
| Geddes, JR | 1 |
| Haslam, D | 1 |
| de Lima, M | 1 |
| Goodwin, G | 1 |
| Gray, NA | 2 |
| Zhou, R | 1 |
| Du, J | 2 |
| Moore, GJ | 2 |
| Harwood, AJ | 1 |
| Agam, G | 1 |
| Nakagawa, S | 1 |
| Koyama, T | 1 |
| Chang, KD | 1 |
| Dienes, K | 1 |
| Blasey, C | 1 |
| Ketter, T | 1 |
| Steiner, H | 1 |
| Harris, M | 1 |
| Chandran, S | 1 |
| Chakraborty, N | 1 |
| Healy, D | 1 |
| Quiroz, J | 1 |
| Denicoff, KD | 1 |
| Singh, J | 1 |
| Charney, DS | 1 |
| Stoner, SC | 2 |
| Dubisar, BM | 1 |
| Lea, JW | 2 |
| Marken, PA | 1 |
| Ramlatchman, LV | 1 |
| Reynolds, JB | 1 |
| Shulman, KI | 1 |
| Sykora, K | 1 |
| Gill, S | 1 |
| Mamdani, M | 1 |
| Bronskill, S | 1 |
| Wodchis, WP | 1 |
| Anderson, G | 1 |
| Rochon, P | 1 |
| Gould, TD | 1 |
| Beresford, TP | 1 |
| Arciniegas, D | 1 |
| Clapp, L | 1 |
| Martin, B | 1 |
| Alfers, J | 1 |
| Yatham, LN | 2 |
| Kennedy, SH | 2 |
| O'Donovan, C | 2 |
| Parikh, S | 1 |
| MacQueen, G | 2 |
| McIntyre, R | 1 |
| Sharma, V | 2 |
| Silverstone, P | 1 |
| Alda, M | 1 |
| Baruch, P | 1 |
| Beaulieu, S | 2 |
| Daigneault, A | 1 |
| Milev, R | 1 |
| Young, LT | 1 |
| Ravindran, A | 1 |
| Schaffer, A | 1 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| Chetcuti, A | 1 |
| Adams, LJ | 1 |
| Mitchell, PB | 1 |
| Schofield, PR | 1 |
| Wolf, AL | 1 |
| Berges, AA | 1 |
| Webster, JP | 1 |
| Lamberton, PH | 1 |
| Donnelly, CA | 1 |
| Torrey, EF | 1 |
| Bergemann, N | 1 |
| Kress, KR | 1 |
| Abu-Tair, F | 1 |
| Frick, A | 1 |
| Kopitz, J | 1 |
| Craig, B | 1 |
| Olsen, A | 1 |
| Swadi, H | 1 |
| Bobier, C | 1 |
| Rachid, F | 1 |
| Golaz, J | 1 |
| Bondolfi, G | 1 |
| Bertschy, G | 1 |
| Mann, K | 1 |
| Hiemke, C | 1 |
| Lotz, J | 1 |
| Schmidt, LG | 1 |
| Lackner, KJ | 1 |
| Bates, DW | 1 |
| Parikh, SV | 1 |
| McIntyre, RS | 1 |
| Bidzan, L | 1 |
| Kamath, J | 1 |
| Temporini, HD | 1 |
| Quarti, S | 1 |
| Pagano, KL | 1 |
| Demartinis, N | 1 |
| Trestman, RL | 1 |
| Savica, R | 1 |
| Beghi, E | 1 |
| Mazzaglia, G | 1 |
| Innocenti, F | 1 |
| Brignoli, O | 1 |
| Cricelli, C | 1 |
| Caputi, AP | 1 |
| Musolino, R | 1 |
| Spina, E | 2 |
| Trifirò, G | 1 |
| Herzog, CJ | 1 |
| Miot, S | 1 |
| Mansuy, IM | 1 |
| Giros, B | 1 |
| Tzavara, ET | 1 |
| Ikeda, M | 1 |
| Thase, ME | 1 |
| Denko, T | 1 |
| Emrich, HM | 1 |
| Altmann, H | 1 |
| Dose, M | 1 |
| von Zerssen, D | 1 |
| Puzyński, S | 1 |
| Kłosiewicz, L | 1 |
| Stip, E | 1 |
| Daoust, L | 1 |
| Gross, R | 1 |
| Grunhaus, L | 1 |
| Kastner, T | 1 |
| Finesmith, R | 1 |
| Walsh, K | 1 |
| Sovner, R | 1 |
| Stone, A | 1 |
| Fox, C | 1 |
| Himelhoch, S | 1 |
| Haller, E | 1 |
| Deltito, JA | 1 |
| Levitan, J | 1 |
| Damore, J | 1 |
| Hajal, F | 1 |
| Zambenedetti, M | 1 |
| Bowden, CL | 2 |
| Vaquerizo, J | 1 |
| Romero-Rodríguez, JC | 1 |
| González-Roncero, A | 1 |
| Gómez-Marcos, A | 1 |
| Eze, E | 1 |
| Workman, M | 1 |
| Donley, B | 1 |
| Dardennes, R | 1 |
| Even, C | 1 |
| Bebchuk, JM | 1 |
| Glitz, D | 1 |
| Hasanat, KA | 1 |
| Goodwin, FK | 1 |
| Facciolà, G | 1 |
| Avenoso, A | 1 |
| Scordo, MG | 1 |
| Madia, AG | 1 |
| Ventimiglia, A | 1 |
| Perucca, E | 1 |
| Ketter, TA | 1 |
| Corá-Locatelli, G | 1 |
| Kimbrell, TA | 1 |
| Davis, JM | 1 |
| Janicak, PG | 1 |
| Hogan, DM | 1 |
| Davis, LL | 1 |
| Ryan, W | 1 |
| Adinoff, B | 1 |
| Petty, F | 1 |
| Donovan, SJ | 1 |
| Stewart, JW | 1 |
| Nunes, EV | 1 |
| Quitkin, FM | 1 |
| Parides, M | 1 |
| Daniel, W | 1 |
| Susser, E | 1 |
| Klein, DF | 1 |
| Hertzman, M | 1 |
| Albanese, MJ | 1 |
| Clodfelter, RC | 1 |
| Khantzian, EJ | 1 |
| Townsend, MH | 1 |
| Cambre, KM | 1 |
| Barbee, JG | 1 |
| Iqbal, MM | 1 |
| Gundlapalli, SP | 1 |
| Ryan, WG | 1 |
| Ryals, T | 1 |
| Passman, TE | 1 |
| Huang, LD | 1 |
| Zeng, WZ | 1 |
| K Manji, H | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Roick, C | 1 |
| Ahrens, B | 1 |
| Becker, T | 1 |
| Deckers, CL | 1 |
| Hekster, YA | 1 |
| Keyser, A | 1 |
| van Lier, HJ | 1 |
| Meinardi, H | 1 |
| Renier, WO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase[NCT01893229] | Phase 4 | 120 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)[NCT00071721] | Phase 3 | 313 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| A Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine[NCT02418702] | Phase 3 | 0 participants (Actual) | Interventional | 2016-08-31 | Withdrawn (stopped due to PI no longer at facility.) | ||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms[NCT00202514] | Phase 2/Phase 3 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver rating questionnaire for the assessment of agitation in older persons. It includes descriptions of 29 agitated behaviors, each rated on a 7-point scale of frequency. The range of this instrument is 29 to 203 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 10.6 |
| Placebo | 12.1 |
Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year (ADAS-cog) is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 42.3 |
| Placebo | 41.9 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Score (ADCS-ADL) is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 78 with lower numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 35.1 |
| Placebo | 41.0 |
Clinical Dementia Rating, Sum of Boxes (CDR-SOB) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 12.0 |
| Placebo | 11.5 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) provides a means to reliably assess global change from baseline. It provides a semi-structured format to allow clinicians to gather necessary clinical information from both the participant and informant, in order to make an overall impression of clinical change. The range of this instrument is 1 to 7 with lower numbers indicating improvement and higher numbers indicating a worsened state. (NCT00071721)
Timeframe: 24 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Valproate | 5.7 |
| Placebo | 5.5 |
NPI quantifies behavioral changes in dementia, including depression, anxiety, psychosis, agitation, and others. This is a questionnaire administered to the subject's study partner. The range of this instrument is 0 to 120 with higher numbers indicating greater impairment. To determine whether or not psychosis or agitation is present, there is no cutoff score but is based on the clinician's judgment. In the NPI, the subject responds to 'Yes' or 'No' questions. Then it is determined how often psychosis or agitation occurs and if it is mild, moderate or severe. (NCT00071721)
Timeframe: 24 months
| Intervention | Participants (Number) |
|---|---|
| Valproate | 25 |
| Placebo | 29 |
35 reviews available for valproic acid and Mood Disorders
| Article | Year |
|---|---|
Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; La | 2021 |
A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD.
Topics: Adult; Affect; Antimanic Agents; Bipolar Disorder; Cognitive Dysfunction; Cross-Sectional Studies; F | 2020 |
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
Lithium and valproate serum level fluctuations within the menstrual cycle: a systematic review.
Topics: Affect; Bipolar Disorder; Female; Humans; Lithium; Male; Menstrual Cycle; Mood Disorders; Valproic A | 2019 |
Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.
Topics: Antidepressive Agents; Carbamazepine; Drug Monitoring; Female; Humans; Lamotrigine; Mood Disorders; | 2014 |
Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Epigenesis, Genetic; Epigenomics; Humans; Lithium | 2018 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions.
Topics: Acetylation; Animals; Antimanic Agents; Epigenesis, Genetic; Gene-Environment Interaction; Histone D | 2011 |
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis.
Topics: Affect; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Diso | 2011 |
Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.
Topics: Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Tolerance | 2011 |
[The optimal combination of ECT with pharmacotherapy].
Topics: Affect; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tric | 2011 |
Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Mood Disorders; Neuroprotective Agents | 2002 |
Valproate for acute mood episodes in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Mood Disorders; Randomized Controlled Trials as Topic; V | 2003 |
The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
Topics: Anticonvulsants; Apoptosis; Atrophy; Brain; Central Nervous System Diseases; Gene Expression; Genes, | 2003 |
Search for a common mechanism of mood stabilizers.
Topics: Affect; Animals; Anticonvulsants; Antimanic Agents; Carbamazepine; Glycogen Synthase Kinase 3; Human | 2003 |
[Mechanism and clinical effects of drugs for mood disorder].
Topics: Antidepressive Agents; Antimanic Agents; Biogenic Monoamines; Humans; Inositol; Lithium; Meta-Analys | 2003 |
Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system.
Topics: Animals; Antidepressive Agents; Antimanic Agents; Glucocorticoids; Glutamates; Humans; Lithium; Mood | 2003 |
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Circadian Rhythm; Disease Models, Animal; Elec | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
[Anticonvulsants treatment of psychiatric disorder in elderly patients].
Topics: Aged; Anticonvulsants; Anxiety Disorders; Bipolar Disorder; Carbamazepine; Epilepsy; Humans; Mental | 2006 |
Effects of mood stabilizer on the circadian system: possible implication for abnormalities in mood disorders.
Topics: 5'-Nucleotidase; Animals; Antimanic Agents; Biological Clocks; Carbamazepine; Circadian Rhythm; Huma | 2007 |
Pharmacotherapy of mood disorders.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder, Major; Diagnosti | 2008 |
A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.
Topics: Affect; Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Disease Progression; Dr | 1996 |
Ring chromosome 22 and mood disorders.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Child; Chromosomes, Human, Pair 22; Drug Therapy, Com | 1996 |
New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine.
Topics: Affect; Anticonvulsants; Humans; Lamotrigine; Mood Disorders; Triazines; Valproic Acid | 1998 |
[Current trends in the therapeutic use of thymic regulators].
Topics: Anticonvulsants; Antidepressive Agents; Depressive Disorder; Female; Humans; Lithium; Mood Disorders | 1998 |
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
Topics: Bipolar Disorder; Calcium-Calmodulin-Dependent Protein Kinases; Carbamazepine; Gene Expression; Glyc | 1999 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
Metabolism and excretion of mood stabilizers and new anticonvulsants.
Topics: Anticonvulsants; Antimanic Agents; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Huma | 1999 |
Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis.
Topics: Antimanic Agents; Carbamazepine; Humans; Lithium Carbonate; Mood Disorders; Prognosis; Recurrence; S | 1999 |
Comprehensive review of the psychiatric uses of valproate.
Topics: Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder, Major; | 2000 |
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Antimanic Agents; Benzodiazepines; Breast Feed | 2001 |
Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Cell Survival; Enoyl-CoA Hydratase; Humans; Intracellul | 2001 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
[Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
Topics: Antimanic Agents; Carbamazepine; Cost-Benefit Analysis; Disease Management; Germany; Humans; Lithium | 2001 |
11 trials available for valproic acid and Mood Disorders
| Article | Year |
|---|---|
Assessing bipolar disorder in the older adult: the GERI-BD toolbox.
Topics: Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Ther | 2018 |
Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms.
Topics: Adolescent; Affective Symptoms; Anticonvulsants; Bipolar Disorder; Child; Child of Impaired Parents; | 2003 |
Extended-release divalproex sodium for mood stabilization.
Topics: Adult; Antimanic Agents; Brief Psychiatric Rating Scale; Delayed-Action Preparations; Humans; Long-T | 2004 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as | 1983 |
Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation.
Topics: Adolescent; Adult; Child; Epilepsy; Female; Humans; Intellectual Disability; Male; Mood Disorders; P | 1993 |
Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescent psychiatric patients.
Topics: Adolescent; Adolescent Psychiatry; Clinical Trials as Topic; Female; Humans; Male; Mood Disorders; P | 1998 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combinatio | 1999 |
Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.
Topics: Adolescent; Ambulatory Care; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; C | 2000 |
Divalproex sodium in substance abusers with mood disorder.
Topics: Adult; Anticonvulsants; Behavior, Addictive; Bipolar Disorder; Comorbidity; Depressive Disorder; Dru | 2000 |
Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cognition Disorders; Double-Blind Method; Drug Ad | 2001 |
40 other studies available for valproic acid and Mood Disorders
| Article | Year |
|---|---|
Waddling Gait: A complication of valproate therapy and a thought beyond vitamin D deficiency.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Epilepsy, Absence; Fem | 2020 |
Lithium use in a patient on haemodialysis with bipolar affective disorder and lithium-induced nephropathy.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Kidney Diseases; | 2021 |
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Anxiety Disorders; Comorbidity; Dissociative Disorders; Epilepsi | 2019 |
Prevalence and clinical presentation of HIV positive female psychiatric inpatients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Cross-Sectional Studie | 2013 |
Valproate as a risk factor for lamotrigine discontinuation.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; | 2013 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
International prescribing patterns for mood illness: the International Mood Network (IMN).
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Asia; Bipolar Disorder; Carbamazepine | 2014 |
Ammonium: the deadly toxin you don't want to miss when using mood stabilizers.
Topics: Adult; Aged, 80 and over; Ammonium Compounds; Female; Glutamic Acid; Humans; Hyperammonemia; Male; M | 2013 |
Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2016 |
The mood stabilizer valproic acid opposes the effects of dopamine on circadian rhythms.
Topics: Animals; Antimanic Agents; Cells, Cultured; Circadian Rhythm; Dopamine; Dopamine Plasma Membrane Tra | 2016 |
Effect of divalproex on brain morphometry, chemistry, and function in youth at high-risk for bipolar disorder: a pilot study.
Topics: Adolescent; Amygdala; Antimanic Agents; Bipolar Disorder; Brain; Brain Chemistry; Child of Impaired | 2009 |
The effects of chronic treatment with mood stabilizers on the rat hippocampal post-synaptic density proteome.
Topics: Animals; Antipsychotic Agents; Drug Administration Schedule; Gene Regulatory Networks; Hippocampus; | 2011 |
[Pancytopenia in the course of acute valproic acid poisoning--case report].
Topics: Epistaxis; Female; Humans; Middle Aged; Mood Disorders; Pancytopenia; Valproic Acid | 2011 |
Ammonemia in bipolar patients on maintenance treatment with valproic acid.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Male; Mood Diso | 2012 |
[Use of convulex in patients with epilepsy with and without affective disorders].
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Gen | 2002 |
Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization.
Topics: Adolescent; Aged; Antimanic Agents; Biological Availability; Bipolar Disorder; Carbamazepine; Drug T | 2002 |
Valproate-induced hyperammonaemia.
Topics: Adult; Antimanic Agents; Emergency Services, Psychiatric; Female; Humans; Hyperammonemia; Male; Midd | 2002 |
Mood-stabilizers: the archeology of the concept.
Topics: Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Concept Formation; Forec | 2003 |
Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study.
Topics: Adult; Age Distribution; Age Factors; Aged; Anticonvulsants; Antidepressive Agents; Benztropine; Coh | 2005 |
Reduction of affective lability and alcohol use following traumatic brain injury: a clinical pilot study of anti-convulsant medications.
Topics: Adult; Alcoholism; Anticonvulsants; Anxiety Disorders; Brain Injuries; Carbamazepine; Female; Humans | 2005 |
Altered gene expression in mice treated with the mood stabilizer sodium valproate.
Topics: Animals; Antimanic Agents; Gene Expression Profiling; Gene Expression Regulation; Male; Mice; Mice, | 2006 |
Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Female; Fructose; Humans; Levetiracetam; | 2005 |
Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour.
Topics: Animals; Antimanic Agents; Antiprotozoal Agents; Antipsychotic Agents; Behavior, Animal; Cats; Dapso | 2006 |
Valproate lowers plasma concentration of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Mood Disorders; Olanzapine; Valp | 2006 |
Mood stabilizer prescribing in a Christchurch adolescent sample: does it comply with guidelines?
Topics: Adolescent; Adolescent Health Services; Adult; Antidepressive Agents; Antimanic Agents; Drug Prescri | 2006 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2006 |
Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders.
Topics: Antimanic Agents; Drug Monitoring; Hospitals, Psychiatric; Humans; Inpatients; Lithium Compounds; Mo | 2006 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
Psychiatric use and utility of divalproex sodium in Connecticut prisons.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Connecticut; Drug Utilization; Female; Humans | 2008 |
Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005.
Topics: Adolescent; Adult; Age Distribution; Aged; Amines; Anticonvulsants; Carbamazepine; Catchment Area, H | 2007 |
Chronic valproate normalizes behavior in mice overexpressing calcineurin.
Topics: Animals; Antimanic Agents; Behavior, Animal; Calcineurin; Cocaine; Disease Models, Animal; Gene Expr | 2008 |
Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders.
Topics: Adult; Bipolar Disorder; Humans; Middle Aged; Mood Disorders; Psychotic Disorders; Recurrence; Valpr | 1984 |
Valproate in the treatment of mood disorder due to multiple sclerosis.
Topics: Adult; Female; Humans; Male; Middle Aged; Mood Disorders; Multiple Sclerosis; Valproic Acid | 1995 |
Choosing lithium, anticonvulsant, or electroconvulsant therapy for mood disorders.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Controlled Clinical Trials as Topic; Electroconvul | 1995 |
Extreme mood lability associated with systemic lupus erythematosus and stroke successfully treated with valproic acid.
Topics: Adult; Antimanic Agents; Cerebrovascular Disorders; Female; Humans; Lupus Erythematosus, Systemic; M | 1996 |
[Partial complex status epilepticus: diagnostic difficulties].
Topics: Anticonvulsants; Child; Crime; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalog | 1998 |
Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder.
Topics: Aged; Ammonia; Anticonvulsants; Coma; Female; Humans; Mood Disorders; Valproic Acid | 1998 |
Introduction: the use of mood stabilizers in the treatment of psychiatric disorders.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; Li | 1999 |
Divalproex sodium to treat concomitant substance abuse and mood disorders.
Topics: Adolescent; Adult; Alcoholism; Bipolar Disorder; Comorbidity; Female; Humans; Male; Middle Aged; Moo | 2000 |
Treatment of borderline personality disorder with mood instability with divalproex sodium: series of ten cases.
Topics: Adult; Antimanic Agents; Borderline Personality Disorder; Female; Humans; Male; Middle Aged; Mood Di | 2001 |